The first new prescription weight-loss pill in more than a decade failed to win backing from U.S. health advisers, who said safety concerns about the drug outweighed its ability to help obese patients shed pounds.
The first new prescription weight-loss pill in more than a decade failed to win backing from U.S. health advisers, who said safety concerns about the drug outweighed its ability to help obese patients shed pounds.
Hopes sank that the first new prescription weight-loss pill in more than a decade would be approved for sale when a key federal advisory panel rejected the drug on Thursday amid lingering safety concerns.
Vivus Inc, hoping to win approval to sell the first new prescription diet drug in more than a decade, told U.S. medical advisers on Thursday its weight-loss pill gives patients a safe option for shedding pounds and improving their health.
(Corrects share price in last paragraph from $2.11 to $12.11)
Vivus Inc, hoping to bring to market the first new prescription diet drug in more than a decade, told U.S. medical advisers on Thursday that its weight-loss pill gives patients a safe option for shedding pounds and improving their health.
GlaxoSmithKline expects to record a legal charge of 1.57 billion pounds ($2.4 billion) for the second quarter after settling the substantial majority of claims relating to its controversial diabetes pill Avandia.
U.S. health experts recommended Wednesday that GlaxoSmithKline's (GSK) diabetes drug Avandia still be sold despite the heart attack risk it poses to patient.
University of Queensland's Australian Institute for Bioengineering and Nanotechnology (AIBN) will produce antibodies for the animal virus Hendra under an accord with Queensland Health and an American foundation.
U.S. advisers neared a vote on whether a GlaxoSmithKline Plc diabetes drug carries too much heart risk to stay on the market, hearing final conflicting pleas Wednesday from a patient and a public health advocate.
The fate of a GlaxoSmithKline Plc diabetes drug may become clearer on Wednesday when U.S. advisers vote on whether the widely used pill carries too much heart risk to stay on the market.
The fate of a GlaxoSmithKline Plc diabetes drug may become clearer on Wednesday when U.S. advisers vote on whether the widely used pill carries too much heart risk to stay on the market.
GlaxoSmithKline Plc has agreed to pay $460 million to settle thousands of lawsuits over its Avandia diabetes pill, Bloomberg reported on Tuesday, on the eve of a crucial vote by U.S. experts on whether the pill should be withdrawn due to heart risks.
A new domestic AIDS policy rolled out by the White House on Tuesday asks states and federal agencies to find ways to cut new infections by 25 percent, get more patients treated quickly and educate Americans about the deadly and incurable virus.
An ambulance patient taken to the Kings County Hospital on Sunday night apparently left a bedbug inside the van forcing the hospital to fumigate part of the emergency room as a precaution against infestation.
Three pharmaceutical companies are vying to get the U.S. Food and Drug Administration's approval for their anti-obesity pills.
BOTOX or botulinum toxin type A has been licensed worldwide as a preventative treatment for chronic migraine.
A new domestic AIDS policy rolled out by the White House on Tuesday looks for new ways to educate people about the deadly and incurable virus, from social media to scientifically sound school campaigns.
A new domestic AIDS policy rolled out by the White House on Tuesday looks for new ways to educate people about the deadly and incurable virus, from social media to scientifically sound school campaigns.
A heated three-year safety debate about a GlaxoSmithKline Plc diabetes pill reaches a climax this week as opponents and backers face off at a U.S. meeting that will help decide the drug's fate.
The U.S. Food and Drug Administration (FDA) has issued a public warning on the use of the weight loss herbal supplement Que She.
Two recent studies linking the diabetes drug Avandia to heart ailments prompted the U.S. Food and Drug Administration (FDA) to consider withdrawing it from the market.
